We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Viatris Inc (VTRS) USD0.01

Sell:$11.83 Buy:$11.84 Change: $0.49 (4.31%)
NASDAQ:2.77%
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$11.83
Buy:$11.84
Change: $0.49 (4.31%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Sell:$11.83
Buy:$11.84
Change: $0.49 (4.31%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.

Contact details

Address:
1000 Mylan Boulevard
CANONSBURG
15317
United States
Telephone:
+1 (724) 5141800
Website:
https://www.viatris.com/en

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VTRS
ISIN:
US92556V1061
Market cap:
$13.10 billion
Shares in issue:
1.19 billion
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Scott Smith
    Chief Executive Officer, Director
  • Theodora Mistras
    Chief Financial Officer
  • Paul Campbell
    Chief Accounting Officer, Corporate Controller
  • Corinne Le Goff
    Chief Commercial Officer
  • Brian Roman
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.